Bronwen Bastone Sells 10,539 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN) insider Bronwen Bastone sold 10,539 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $8.17, for a total transaction of $86,103.63. Following the sale, the insider now owns 217,154 shares of the company’s stock, valued at approximately $1,774,148.18. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Bronwen Bastone also recently made the following trade(s):

• On Thursday, June 20th, Bronwen Bastone sold 18,241 shares of Enfusion stock. The shares were sold at an average price of $8.11, for a total value of $147,934.51.

Enfusion Stock Performance

ENFN opened at $8.36 on Wednesday. Enfusion, Inc. has a fifty-two week low of $7.52 and a fifty-two week high of $11.56. The company has a market capitalization of $1.07 billion, a P/E ratio of 278.76, a P/E/G ratio of 1.93 and a beta of 0.96. The stock has a fifty day moving average of $9.11 and a 200-day moving average of $9.08.

Enfusion (NYSE:ENFN) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The company had revenue of $48.05 million during the quarter, compared to analyst estimates of $47.67 million. Enfusion had a net margin of 1.40% and a return on equity of 6.60%. During the same period last year, the firm earned $0.04 EPS. On average, equities research analysts predict that Enfusion, Inc. will post 0.09 earnings per share for the current fiscal year.

Institutional Trading of Enfusion

Several hedge funds and other institutional investors have recently made changes to their positions in ENFN. Allspring Global Investments Holdings LLC bought a new stake in Enfusion in the first quarter valued at approximately $44,000. Tower Research Capital LLC TRC raised its position in shares of Enfusion by 680.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 9,894 shares of the company’s stock worth $96,000 after purchasing an additional 8,627 shares during the period. Barclays PLC raised its position in shares of Enfusion by 29.0% during the third quarter. Barclays PLC now owns 10,809 shares of the company’s stock worth $96,000 after purchasing an additional 2,430 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in shares of Enfusion during the first quarter worth approximately $102,000. Finally, Quadrature Capital Ltd bought a new stake in Enfusion during the first quarter worth $109,000. 81.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ENFN shares. Morgan Stanley initiated coverage on Enfusion in a research note on Friday, May 10th. They issued an “overweight” rating and a $11.00 price target for the company. The Goldman Sachs Group downgraded Enfusion from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $9.00 to $8.00 in a report on Wednesday, February 28th. Finally, Bank of America lifted their target price on Enfusion from $8.00 to $9.00 and gave the stock an “underperform” rating in a report on Wednesday, March 13th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.33.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.